Clinical application and development of anti-cancer drugs on the basis of molecular classification of gastric carcinoma

Sha LIU,Ya LI,Bin WANG,Dongfeng CHEN
DOI: https://doi.org/10.3969/j.issn.1006-5709.2018.11.001
2018-01-01
Abstract:Gastric carcinoma is the most prevalent gastrointestinal cancers in China. Clinical application and development of anti-cancer drugs is challenging due to heterogeneity of gastric carcinoma and precise classification of the tumor is highly warranted. However, in clinical settings, gastric carcinoma is usually diagnosed by histological and morphological features, such as those mentioned in Borrmann classification, Lauren classification and WHO classification. These classification criteria could not meet the need of precision medical oncology. In this regard, several molecular classification systems of gastric carcinoma are recently established on the basis of The Cancer Genome Atlas ( TCGA) and application of deep sequencing techniques. Among those, the TCGA and ACRG classification systems are most widely accepted. In these systems, gastric carcinoma can be classified based on distinct genetic, epigenetic and expression profiles. They are very useful tools for clinicians to prescribe or design anti-cancer therapies. Here, the most exciting achievements being made around the world are introduced briefly. How these molecular classification systems provide rationale for anti-cancer therapy in clinics as well as developing new drugs in industry are analyzed. This molecular approach may lead to groundbreaking discoveries in targeted and immune therapies against gastric carcinoma and bring a new era of precision cancer medicine.
What problem does this paper attempt to address?